<DOC>
	<DOCNO>NCT00000798</DOCNO>
	<brief_summary>To evaluate safety immunogenicity new microparticulate formulation HIV-1 MN PND peptide oral administration healthy , HIV-1 seronegative adult volunteer low risk infection . Vaccine formulation synthetic peptide adsorb alum may provide requisite characteristic effective HIV vaccine , induction mucosal immunity , production cytotoxic T cell , ease administration . An oral microparticulate vaccine contain prototype synthetic peptide develop . The microparticles degrade time , induce secretory systemic immune response .</brief_summary>
	<brief_title>A Phase I Safety Immunogenicity Trial UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen HIV-1 Seronegative Human Subjects</brief_title>
	<detailed_description>Vaccine formulation synthetic peptide adsorb alum may provide requisite characteristic effective HIV vaccine , induction mucosal immunity , production cytotoxic T cell , ease administration . An oral microparticulate vaccine contain prototype synthetic peptide develop . The microparticles degrade time , induce secretory systemic immune response . Twelve volunteer per dose regimen receive oral microparticulate multivalent HIV-1 peptide vaccine month 0 , 1 , 6 , either daily low dose 3 day single high dose . Additionally , four volunteer per regimen receive placebo . Volunteers follow 1 year . They contact twice yearly 5 year check health status .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . HIV negativity ELISA within 8 week study entry . Absolute CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . Lower intermediate risk sexual behavior . NOTE : No 10 percent subject may 50 year age . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition ( psychosis suicidal tendency ) occupational responsibility preclude study compliance . Active syphilis . NOTE : Subjects whose serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease . History anaphylaxis serious reaction vaccine . History inflammatory gastrointestinal disease , celiac disease , intestinal malignancy . History acute gastroenteritis within past month gastrointestinal surgery within past year . History cancer unless surgical excision reasonable assurance cure . History serious allergic reaction . Prior Medication : Excluded : History immunosuppressive medication . Live attenuate vaccine within 60 day prior study entry ( NOTE : Medically indicate subunit kill vaccine , e.g. , influenza pneumococcal , exclusionary , give within 2 week HIV immunization ) . Experimental agent within 30 day prior study entry . Prior HIV vaccine . Prior Treatment : Excluded : Blood product immunoglobulin within past 6 month . Identifiable high risk behavior HIV infection , include follow : History injection drug use within past 12 month . Higher risk sexual behavior define AVEG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>